Method of predicting of process activation in patients with hodgkin's lymphoma

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to biochemical investigations in oncology, and can be used in determination of activation or stabilisation of pathologic process in patients with primary-resistant Hodgkin's lymphoma. In patients with primary-resistant Hodgkin's lymphoma at stages of treatment, by radioimmune method determined is content in blood of thyroid gland hormones - triiodothyronine and thyroxine, and adrenocortical hormone - cortisol, their concentration is summed up and in case of total level of hormones is within 278.2 nmole/l - 0 333.0 nmole/l conclusion about activation of malignant process is made, if total level of said hormones is 432.4 nmole/l - 833.2 nmole/l conclusion about absence of process activation is made.

EFFECT: prediction of process activation or stabilisation in patients with primary-resistant Hodgkin's lymphoma is an informative test for evaluation of pathologic process state and can be recommended for monitoring of patients at treatment stages.

1 tbl, 2 ex

 

The invention relates to medicine, namely to biochemical research in Oncology and can be used to determine the activation or stabilization of the pathological process in patients with primary refractory Hodgkin's lymphoma.

Despite the fact that Hodgkin's lymphoma (Hodgkin's disease) are related to neoplastic diseases of the blood forming organs, which are most often exposed to successful recovery, nevertheless the actual problem in the field of Oncology remains the treatment of patients with primary resistant (refractory) forms of the process. In particular, this applies to situations where, in the absence of clinical effect of the applied treatment in patients marked activation of malignant growth that can lead to generalization of the disease and require changes to the schemes and tactics of therapeutic interventions. In this regard, given the high importance of timely detection of the activation direction of the process, one of the important tasks is to support search of additional laboratory tests, the use of which during the treatment period, usually long-term in patients with Hodgkin's lymphoma, will identify possible changes in the course of the disease.

Known "Way to determine the clinical factors of poor prognosis for lymphoma X is Gcina": age over 45 years, increased levels of alkaline phosphatase in serum by more than 50% of the upper limit of normal, the number of zones lesions more than 5, conglomerated lymph nodes of size 5 cm or more, male gender, serum albumin less than 4.0 g/DL, hemoglobin less than 10.5 g/DL, lymphocytopenia less than 0.6×109/l (Kanaev SV and others, 2005). However, female patients with this pathology to unfavorable prognostic signs include a decrease in blood estradiol, progesterone and testosterone.

Listed prognostic factors are summarized and analyzed in the individual planning treatment tactics for patients with Hodgkin lymphoma. It is known, however, that the tumor development, even with the same source factors can vary significantly in each case. This is due to the biological properties of the tumor and to a large extent a particular state of the body, affecting the nature of the interaction in the system between the tumor and the body. In this regard, clinical prognostic factors may not be used for individualization of the state of the malignant process in patients with Hodgkin's lymphoma.

There is a method of prognosis in patients with Hodgkin's lymphoma on the content in the serum of lymphocytes s25 at the beginning of the disease (Puri C.H. et al. Zeukemia, 1993), selected the us as a prototype. The authors found that in this category of patients in the initial stages of development of malignant lymphoproliferative process serum levels s25 differ significantly. The researchers found a link of the specified index with the prognosis of the disease - it turned out to be favorable at low concentrations s25 in the blood and adverse when it is elevated values. The disadvantages of this method include low information content of the proposed test in relation to the characteristics of the activity of the pathological process that is important in the treatment of patients with refractory forms of Hodgkin's lymphoma.

According to modern concepts of thyroid hormones and cortisol are in the body of the main regulators of all types of metabolism - protein, carbohydrate, lipid, mineral. This function Dolny bioactive compounds provides the control, regulation and maintenance of adequate levels of General homeostasis of the organism. However, in addition to the regulation of metabolism, thyroid hormones and adrenal glands play a multifunctional role as a multipurpose bioregulators systemic effects at the cellular, tissue and organ levels, determining the development of numerous and diverse physiological effects. Gorani control about Icemist membranes, synthesis of highly specialized proteins, the activity of cellular organelles, the state of lymphoid organs and in the whole immune system, oxygen supply to tissues, the intensity of energy metabolism, improve blood. One of the important properties of these hormones is also their participation in the mechanisms of resistance of the organism and its adaptation to changing how exogenous and endogenous conditions. All of the above suggests that the status of thyroid hormones and cortisol in patients with cancer can have a significant impact on the characteristics of the reaction to the development of malignant tumors.

The aim of the invention is to determine the state of activation or stabilization of the pathological process in patients with Hodgkin's lymphoma during treatment.

This objective is achieved in that in patients with primary refractory Hodgkin's lymphoma during treatment, radioimmunoassay method determines the blood levels of thyroid hormones - triiodothyronine and thyroxine, the hormone of the adrenal cortex - cortisol, summarize their concentration and total amount of hormones in the borders 278,2 nmol/l 333,0 nmol/l state activation malignant process, and with the General level of these hormones 432,4 nmol/l 833,2 nmol/l note the absence of the activation process.

The image is giving "a Method for predicting the activation process in patients with Hodgkin lymphoma" is a new, as it is unknown the level of medicine in the field of biochemical research for predicting the course of the pathological process in patients with primary refractory Hodgkin's lymphoma.

The novelty of the invention lies in the fact that for the assessment of the pathological process in patients with Hodgkin's lymphoma using the overall content in the blood of the basic multi-hormone regulators - triiodothyronine, thyroxine and cortisol. Total concentration in the blood of patients triiodothyronine, thyroxine and cortisol in the borders 278,2 nmol/l 333,0 nmol/l indicates the activation of a malignant process, and with the General level of these hormones within the boundaries 432,4 nmol/l 833,2 nmol/l note the absence of the activation process.

The invention of "a Method for predicting the activation process in patients with Hodgkin's lymphoma is promissao applicable, as may be used in health care, in hospitals specialized profile for the treatment of cancer patients with this malignant process.

"A method for predicting the activation process in patients with Hodgkin's lymphoma as follows.

The study included 5 patients with Hodgkin lymphoma (HL) with 2B-3b-stage disease at the age of 29-39 years.

By the time of the study serum hormones ill the e received several courses of chemotherapy + remote gamma-therapy radical programme. In the blood of patients radioimmunoassay method was determined by the content of the thyroid hormones thyroxine (T4) and triiodothyronine (T3and the main glucocorticoid hormone of the adrenal cortex cortisol. Then calculate the overall level of hormone regulators by adding their concentrations (T3+T4+cortisol).

Determination of total concentration in the blood of patients with HL thyroid hormones and cortisol showed that 3 out of 5 women total content of hormones controls ranged from 432,4 nmol to 833,2 nmol/l and in 2 other patients, the figure was 273,2 and 338,0 nmol/L. Held simultaneously with the study of the hormonal profile of the control patients revealed in the last two cases, the activation of the pathological process and the lack of activation in the first 3 cases.

Thus, the obtained data indicate that activation of the malignant process in women with LH is associated with low overall level in the blood of patients with thyroid hormones and cortisol, equal 273,2-338,0 nmol/L. In contrast, the hormones in the absence of the activation process is characterized by high values of the total amount of hormones in the borders 432,4-833,2 nmol/L.

The results presented indicate the high relevance of the proposed test assessment of the pathological process in Bo is lnyh with LH on the size of the total content in the blood of thyroid hormones and cortisol. The test can be recommended as additional laboratory factor evaluation in the monitoring of patients on LH stages of treatment.

The total content of thyroid hormones and cortisol in the blood of patients with HL, depending on the state of the malignant process
Patients with activation processPatients without activation process
1. 273,2 nmol/l1. 43 2.4 nmol/l
2. 338,0 nmol/l2. 811,5 nmol/l
3. 833,2 nmol/l

Clinical examples of the application of the Method for predicting the activation process in patients with Hodgkin lymphoma"

Example No. 1. B-I D., born in 1979, istby. No. 9418/08, on treatment with December 2008 Diagnosis: LGM Art. IIIB (IGR) with peripheral l/y (neck lymph nodes on the left), the lymph nodes in the mediastinum, zabroshenyj l/y. Left-sided pleural effusion. G/a from 03.12.08 - Hodgkin's lymphoma (No. 7328-7332). Source: had enlarged cervical lymph nodes on the left up to 2-3 cm in diameter, dense, sedentary, sensitive to palpation, itchy skin, night sweats, subfebrile body temperature, weakness, SKT SSB and ultrasound SSB - uvelicheny zaproszenie lymph nodes (many small) on SKT UCP - an enlarged lymph node mediastinal, left-sided pleural effusion. The patient received 2 courses of 45 mm/hour, PCT ABVB - clinically insignificant improvement - l/have not diminished, disappeared skin itching, sweating is not decreased, l/mediastinal and retroperitoneal l/y is unchanged.

At this stage, the patient carried out the determination in blood content of thyroid hormones and cortisol, their total concentration (T3+T4+cortisol) is 833,2 nmol/L.

Thus, the patient with the lack of activation of the process at the stage of treatment is high level in the blood of the main hormones of the controllers.

Example No. 2. B-I D., born in 1969, East. bol. No. 1522/91. Diagnosis: LGM STB (ex) mixed-cell variant, with peripheral l/u (cervical-over-subclavian, axillary l/u), mediastinal l/y. Is being treated since 1991. Received mnogochasovuyu PCT+DHT radical programme. In 2008, the activation process. Complaints at admission: weakness, constant sweating, itching, subfebrile body temperature in the evening. St. localis: increased cervical-over-subclavian lymph nodes up to 2.5 cm in diameter, dense, sedentary palpation, axillary l/u - up to 1.5 cm in diameter, dense, sedentary, sensitive to palpation with both sides.

23.XII.08, estimation of blood sick content of thyroid hormones and to the Tizol, their total concentration (TK+T4+cortisol) was 278,2 nmol/L.

Thus, the activation process of the patient combined with low overall levels of thyroid hormones and adochnikov.

Technical and economic efficiency of the Method for predicting the activation process in patients with Hodgkin lymphoma" is that the prediction of activation or stabilization process in patients with primary refractory Hodgkin's lymphoma in blood levels of thyroid hormones and cortisol is informative test for the assessment of the pathological process and can be recommended for monitoring patients during treatment.

A method for predicting the activation process in patients with Hodgkin's disease, including biochemical, characterized in that in patients with primary refractory Hodgkin's lymphoma during treatment radioimmunoassay method determines the blood levels of thyroid hormones - triiodothyronine and thyroxine, the hormone of the adrenal cortex - cortisol, summarize their concentration and total amount of hormones in the borders 278,2 nmol/l 333,0 nmol/l state activation malignant process, and with the General level of these hormones 432,4 nmol/l 833,2 pmol/l note the absence of the activation process.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology and vascular surgery. The sex hormones level in an involved vein is considered to be a criterion of the severity level of varicocele. There are evaluated the following sex hormones: testosterone, estradiol, progesterone simultaneously in the pampiniform plexus veins of a left ovary and in the peripheral vein of a bend of elbow, with determining the ratio of the sex hormones level in a healthy vein of the bend of elbow to the varicocele-involved pampiniform plexus vein. If said ratio of the sex hormones level is 1:10 to 1:50, the first degree of varicocele is diagnosed. Recurrent varicocele and the second degree of varicocele is diagnosed by the ratio of the sex hormones level in the healthy and involved veins 1:50 to 1:100 times (i.e. hormones concentration in a varicose vein is increased in tens times). If observing the ratio of the sex hormones level in the healthy vein and the involved vein of the pampiniform plexus veins of the left ovary increasing more than in 1:100, the third degree of varicocele is diagnosed. Surgical intervention is indicated if the ratio of the sex hormones level is diagnosed more than 1:50.

EFFECT: method allows improving diagnostic accuracy of varicocele severity and diagnosing the recurrence on the basis of objective numerical information, and also accurately stating indications for varicocele surgery.

5 cl, 4 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to biochemistry, surgery and dentistry. The bone resorption to remodeling analysis is based on the biochemical blood examination. An the blood coefficient K1 is calculated by formula: K1=[(PTH:A)+(TNF-α:B)+(IL-1β:C)]:3, where PTH is the parathyroid hormone concentration (pg/ml) in the patients, A is the same value in healthy individuals, TNF-α is the level of tumor necrosis factor -α (pg/ml) in the patients, B is the same value in healthy individuals, IL-1β is the interleukin-1β concentration (pg/ml) in the patients, C is the same value in healthy individuals to derive the blood coefficient K2 by formula: K2=[(calcitonin: D) + (osteocalcin: E)]:2, where the calcitonin concentration (ng/ml) in the patients, D is the same value in healthy individuals, the osteocalcin level (ng/ml) in the patients, E is the same value in healthy individuals. Then the bone metabolism control coefficient (BMCC) is calculated by formula BMCC=K1:K2, and the higher BMCC than 1.17, the more intensive resorption prevails over remodelling; and the lower BMCC than 0.83, the more intensive remodelling prevails over resorption.

EFFECT: method allows high accuracy detection of prevalence of resorption or remodelling intensity in the bone stock metabolism control in practically healthy individuals (monitoring) and in pathology cased for the purpose of diagnosis, assessment and therapeutic prognosis.

5 tbl, 3 dwg, 2 ex

FIELD: veterinary science.

SUBSTANCE: method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease.

EFFECT: early diagnostics of kidney function abnormalities in felines.

20 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: there are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.

EFFECT: use of the invention allows optimising diagnosis of foetal maturity, reducing number of infants suffering morphofunctional immaturity and overmaturity signs, and determining optimum delivery date, improving the perinatal outcome in pregnant women on their 37-42 weeks of pregnancy.

3 ex

FIELD: medicine.

SUBSTANCE: method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.

EFFECT: clinical application of the method allows for well-timed administration of the appropriate treatment in the patient with high-risk early process generalisation.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.

EFFECT: use of the invention allows determining sensitivity of the recurrent breast cancer to the neoadjuvant automyelochemotherapy for an individual correction of treatment policy in patients with said pathology.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency.

EFFECT: higher accuracy of clinical assessment of severity of trophological insufficiency in the patients with chronic obstructive pulmonary disease.

4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: in patients suffering from larynx cancer after surgical oncotomy in the course of dispensary observation levels of androsteron and estradiol in 24-hour collection urine are examined and their ratio to each other are determined. At ratio level more than 3 emergence of disease retrocession or metastasis in the near future is forecasted. At ratio level lower than 3 a long-lasting recurrence-free period is forecasted.

EFFECT: use of this method enables to forecast emergence of larynx cancer retrocession and to assume measures to individualise therapeutic modality.

2 ex

FIELD: medicine.

SUBSTANCE: diagnostic technique for desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma refers to medicine. Substance consists that blood of the patients is radioimmunoassayed for concentration of TSH, T3, T4 hormones. The obtained data are processed to draw a graphic curve of circadian rhythm for each hormone that provides a basis to determine individual acrophase and batiphase time. The acrophase (confidence interval) TSH development biorhythm 9 h 11 min (confidential interval 4 h 57 min to 13 h 26 min), T3 hormone - 15 h 01 min (confidential interval 8 h 05 min to 21 h 57 min) T4 hormone - 16 h 34 min (confidential interval 8 h 55 min to 24 h 13 min), and batiphase of circadian TSH secretion rhythm 21 h to 22 h, T3 - 2 h to 4 h, T4 4 h to 5 h ensure to diagnose apparent desynchronosis of hypophysial thyroid system.

EFFECT: application of the method allows to detect desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma, previously not taking glucocorticoid therapy and thereby prescribing an individual regimen of chronotherapy, enabling monitoring during treatment for a complex estimate of clinical effectiveness, reducing frequency of collateral actions, ensuring earlier remission and reducing time of staying in hospital.

2 ex, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and veterinary science and can be used for predicting depressive behaviour of an aged primate, rates of ageing and development of stress-dependent pathological changes. According to the claimed invention, an aged primate is examined for psychoemotional reaction on soft and acute psychoemotional stress effect, molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma and percentage concentration of cortisol in peripheral blood plasma in the evening (20 o'clock 45 minutes - 21 o'clock 15 minutes) to concentration of cortisol in peripheral blood plasma in the morning (8 o'clock 45 minutes - 9 o'clock 15 minutes) to predict depressive behaviour in the aged primate with accelerated rates of ageing and development of stress-dependent pathological changes in depressive reaction on soft and acute psychoemotional stress effect, if molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma is not less than 4.3, and concentration of cortisol in peripheral blood plasma in the evening to concentration of cortisol in peripheral blood plasma in the morning is not less than 66%.

EFFECT: ensured information value of predicting depressive behaviour in the aged primate, rates of ageing and development of stress-dependent pathological changes.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to obstetrics, and can be used for prediction of preterm effusion of amniotic fluid in pregnant women with gestation term 32-36 weeks. Essence of invention lies in the following: in blood serum of pregnant women with gestation term 32-36 weeks IL-8 level is determined, and if its value equals or is lower than 15.4 ng/ml, preterm effusion of amniotic fluid is predicted.

EFFECT: method is simple in implementation and allows to predict development of preterm effusion of amniotic fluid with high accuracy, sensitivity and specificity, which makes it possible to select correct tactics of monitoring women with risk of said obstetrics pathology development, to avoid complications of labour activity and perinatal pathology.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to diagnostic methods and deals with method of diagnosing entry of nuclei of placenta pili syncyotrophoblast into apoptosis by determining in placenta homogenate content of IgG and IgM antibodies to phosphatidylserine in pregnant women, who had herpes-virus infection in the third trimester of pregnancy. Method lies in determination of IgG and IgM antibodies to phosphatidylserine in placenta homogenate by ELISA method. If titre of antibodies to HSV-1 equalled 1:6400, 4.70±0.08 U/ml of IgG and IgM antibodies to phosphatidylserine were detected; if titre was 1:12800, content of IgG and IgM antibodies to phosphatidylserine increased to 5.60±0.06 U/ml (control - 2.50±0.07 U/ml), number of syncyotrophoblast nuclei in state of apoptosis constituted 4.50±0.20% (control - 1.5±0.20%).

EFFECT: method possesses high sensitivity and allows to predict development of apoptosis in nuclei of placenta pili syncyotrophoblast in case if number of IgG and IgM antibodies to phosphatidylserine in placenta grows.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to biochemical investigations in oncology, and can be used in treatment of Hodgkin's lymphomas with primary drug resistance of tumour to standard schemes of drug intervention. Novelty and essence of investigation lies in the following: in patients with Hodgkin/s lymphoma at treatment stages by radioimmune method determined is content in blood of total and free thyroxine, coefficient of ratio of concentrations total thyroxine/free thyroxine is determined and if its values are within 8.4-11.2 conclusion about absence of clinical effect of anti-tumour therapy is made, if coefficient values are within 14.2-22.8, conclusion about presence of clinical effect of treatment is made.

EFFECT: laboratory biochemical analysis determines clinical efficiency of the method or its absence during treatment procedures in patients with application of standard chemichal therapy, autolymphochemical therapy and is valuable laboratory test for determination of treatment efficiency and further tactics of patients monitoring.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurology. Risk factors are determined from history of life: family history of cardio-vascular disease, hypertension disease and in case of its presence regularity of anti-hypertensive therapy intake, marital status, age, education, psychoemotional stress, sex, also taken into account is expression of detected during first examination cognitive impairment and results of its treatment. Their gradations and numerical values are determined, prognostic coefficients F1, F2 are calculated by mathematical formulas with further comparison of their values. If F1 is higher than F2 favourable type of cognitive impairment course in patients with ischemic stroke is predicted, and if F2 is higher than F1 - unfavourable type of cognitive impairment course.

EFFECT: method ensures possibility of estimation of clinical course of cognitive impairment, thus allowing to increase efficiency and purposefulness of preventive and medicinal measures in groups of patients with risk of developing unfavourable course of cognitive impairment.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pedagogics, and can be used in activities of medical, health and sport institutions, method of estimating efficiency of sport and recreation activities at secondary educational institution. Physical fitness is determined by indices of hemodynamic components of cardio-vascular system and index of physical development. Diagnostics of conditions, process and result of institution activity is performed by criteria: value, aim, organisation-activity, health-preservation. On the basis of calculated criteria determined is integral coefficient of sport and recreation activities, which indicates of efficiency of sport and recreation activities at secondary educational institution.

EFFECT: method allows to carry out comprehensive analysis of institution activities by directions, evaluate efficiency of sport and recreation activities in structure of health-preserving activity of secondary educational institution, detect shortcomings and perform targeted correction of detected violations by realisation of elaborated measures.

13 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to traumatology, orthopedics and immunology. In order to predict prosthesis instability in endoprosthetics of large joints, analysis of immunologic parametres in patient's peripheral bloodbefore operation is carried out. Cells of peripheral blood are incubated without stimulation with mitogen and with stimulation with bacterial lipopolysaccharide. In obtained supernatants concentration of TNF-a (Tumor Necrosis Factor-α) is determined. Stimulation index is determined by ratio of stimulated TNF-α product to its spontaneous level. If determined index value is higher than 2.5 high risk of development of instability of endoprosthesis components is predicted.

EFFECT: method allows to increase objectivity of prediction of development of prosthesis instability due to earlier determination of individual immunologic reactivity of organism to damaging factors of various types and to perform immunologic rehabilitation of patients in due time, as well as to simplify technology of prediction and reduce multiplicity of laboratory reaseach.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to method of predicting preventive and/or therapeutic effect of RAR-α agonist in oncological patients. In order to realise the method, level of expression of molecules of family p160, such as AIB1, SRC-1, TIF2, and level of expression of molecules of family SP110b in sample, taken from patient's malignant tumour, are determined and ratio between said levels of expression is determined. In case if ratio "level of AIB1 expression/ level of SP110b expression" is higher than 0.240, it is considered that RAR-α agonist is efficient in therapeutic treatment of patient's malignant tumour. Similar conclusion is made if value of ratio "level of SRC-1 expression/ level of SP110b expression" exceeds 0.662, as well as in case if value of ratio "level of TIF2 expression/ level of SP110b expression" exceeds 0.141. In case if said values of ratio of expression levels is detected, patient is introduced RAR-α agonist for treatment of malignant tumour, such as cancer of liver.

EFFECT: application of claimed method allows to predict efficiency of treatment with RAR-α agonists quite accurately.

10 cl, 5 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to physiotherapy. Sonographic examination is carried out. Clinical parametres are determined. In position when patient is lying on their stomach determined are direction of passing of osteomiotonic picture vector E→VB and syndrome II - "rupture of top-bottom", and if vector E→VB passes to the left of point VG11, or presence of syndrome II, deposition of bile in biliary tract is determined, and if vector E→VB passes to the right of point VG11 and syndrome II is absent, presence of only hepatocytic cholestasis is determined, then according to the first state at the moment of pause between patient's inhalation and exhalation performed is stretching of hypochondria regions by pronation and lifting of shoulder joints using as "levers" patient's wrists, in case of the second state - also between inhalation and exhalation performed is compression of diaphragm surface of right liver lobe with lung and diaphragm by means of pronation and descend of right shoulder joint and bringing right shoulder-blade to spine bone, using as a lever patient's right wrist, with simultaneous lifting of left hypochondrium by means of pronation and lifting of left shoulder joint respectively by patient's left wrist. Correcting manipulations are performed 4-6 times at each session.

EFFECT: simple in application method allows to reduce risk of complications.

3 cl, 4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to diagnostics. In sweat fluid, obtained as a result of performing physical exercise or heating body in sauna, heat cabin real (ε') and imaginary (ε") parts of complex dielectric permeability at frequency 0.3-1.2 GHz are measured many times. Mass concentration (S) is calculated by formulas: S=(ε'-a)/b·or S=(ε"-c)/d, where a, b, c, d are numerical coefficients for different body parts: left arm: a=81.0, b=18.0, c=4.1, d=1629, right arm: a=82.0, b=-63.7, c=3.2, d=1895, left leg: a=81.2, b=5.3, c=4.3, d=1618, right leg: a=81.1, b=-57.2, c=1.02, d=1963, face: a=81.4, b=-52.9, c=7.1, d=1459, chest and stomach: a=82.2, b=-142, c=8.4, d=2250. Orientation of time derivative trends ε'(τ) and ε"(τ) is determined. In case of orientation, functional state is estimated as state without pathology, in case of , , , orientation as state with present pathology.

EFFECT: method allows to carry out express diagnostics of diseases associated with water-salt disbalance.

3 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine and may be used for preoperative prediction of ulcerous complications in gastrointestinal tract in cardiac surgery patients. For this purpose 2-3 days prior to operation, before and after general hypoxic test, endogastric pH is measured. General hypoxic test is carried out by inhalation of gas mixture with 10% content of oxygen for 40 minutes. If pH reduces twice and more, risk of ulcerous complications development in postoperational period is considered high.

EFFECT: method makes it possible to determine increasing acid-producing function of stomach in response to hypoxic stress and factor of risk of development of ulcerous complications in gastrointestinal tract in cardiac surgery patients of postoperational period and to build rational preventive therapy on the basis of available data.

2 ex

FIELD: medicine, clinical toxicology.

SUBSTANCE: at patient's hospitalization one should gather the data of clinical and laboratory values: on the type of chemical substance, patient's age, data of clinical survey and laboratory values: body temperature, the presence or absence of dysphonia, oliguria being below 30 ml/h, hemoglobinuria, erythrocytic hemolysis, exotoxic shock, glucose level in blood, fibrinogen and creatinine concentration in blood serum, general bilirubin, prothrombin index (PTI), Ph-plasma, the state of blood clotting system. The state of every sign should be evaluated in points to be then summed up and at exceeding the sum of points being above "+20" one should predict unfavorable result. At the sum of "-13" prediction should be stated upon as favorable and at "-13" up to "+20" - prediction is considered to be doubtful.

EFFECT: higher accuracy of prediction.

2 ex, 3 tbl

Up!